Peptora Get app
← All peptides

Tirzepatide

★ 96 FDA approved

Tirzepatide (Mounjaro, Zepbound)

Dual GLP-1/GIP agonist — stronger than Semaglutide

Fat Loss
Half-life
~5 days
Route
SubQ
Cycle
Not cycled. Long-term
Status
FDA approved (Mounjaro 2022

About

A dual agonist that activates both GLP-1 and GIP receptors. FDA approved 2022. Shows 20-22% weight loss in clinical trials.

Mechanism

Activates both GLP-1 and GIP, producing synergistic effects on glycemic control, insulin sensitivity, and adipose-tissue regulation.

Dosage

beginner

Amount
2.5 mg
Frequency
1x per week for 4 weeks
Route
SubQ
Duration
Titration phase

standard

Amount
5 mg → 7.5 mg → 10 mg
Frequency
1x per week, increasing every 4 weeks
Route
SubQ
Duration
16-20 weeks

advanced

Amount
12.5 mg → 15 mg (max)
Frequency
1x per week
Route
SubQ
Duration
Long-term
Timing

Same day each week. Any time of day, with or without food.

Cycle structure

Not cycled. Long-term use with taper if discontinuing.

Reconstitution & Storage

10 mg + 2 mL → 5 mg/mL

Compounded version. Prescription pen is pre-filled.

Refrigerated 2-8°C. Compounded: 30-56 days after reconstitution.

Benefits

  • • 20-22% weight loss (SURMOUNT trials)
  • • Stronger effects than Semaglutide (head-to-head trial)
  • • Improved glycemic control
  • • Lowered blood pressure
  • • Improved lipid profile

Side effects

  • • Nausea (common initially)
  • • Diarrhea
  • • Reflux
  • • Constipation
  • • Abdominal pain

Contraindications

  • • Medullary thyroid carcinoma
  • • MEN 2 syndrome
  • • Pregnancy
  • • History of pancreatitis
  • • Severe gastrointestinal disease

Gender notes

Men

Same dose. Sometimes more pronounced weight loss than in women.

Women

Same dose. May reduce oral contraceptive efficacy (use backup contraception for the first 4 weeks after each dose increase).

Research

Stacks well with

BPC-157 IPAMORELIN

Track Tirzepatide doses in the app

Built-in reconstitution calculator, dose log, and reminders. Free on Android.

Get on Google Play

Educational use only. Not medical advice. Many peptides shown are not FDA-approved and remain research compounds. Always consult a qualified healthcare provider.